Austrian Exhibitors at BIO-Europe 2013 by Sonja Polan

BIO Europe 2013 Austrian Exhibitors

BIO-Europe 2013 November 4 â&#x20AC;&#x201C; 6 Vienna, Austria

Welcome to Vienna! We are very proud to host BIO-Europe, the worldâ&#x20AC;&#x2122;s largest stand-alone partnering event for a second time after 2009. The 19th annual edition of BIO-Europe, will gather leaders of the life science industry at the Wiener Messe to take biotech dealmaking to a new level. Austria prides itself on a long tradition of revolutionary discoveries in the life sciences, with such famous names as Theodor Billroth, Karl Landsteiner and Max Perutz. But today, too, or perhaps especially today, Austria has a wealth of innovative potential to offer. A thriving environment of successful and innovative companies has put Austria firmly on the European life science map. The combination of global players with research facilities in Austria and young, dynamic start-ups in close cooperation with excellent universities creates an ideal environment for the development, growth and prosperity of the Austrian life science industry. The following pages will give you a brief overview about the Austrian companies and research organisations participating at BIO-Europe. 102 of the most innovative Austrian biotech companies and research organisations as well as Austrian regional cluster organisation will present their products and services to the international biotech scene. We hope you will enjoy your stay in Vienna, thanks to its grand historic buildings as well as its cutting-edge biotech technologies. Donâ&#x20AC;&#x2122;t miss the opportunity to get to know better the Austrian burgeoning life sciences industry and its innovative companies at our Austrian pavilion. See you there!

Mag.a Edeltraud Stiftinger Managing Director Austria Wirtschaftsservice GesmbH

Life Science Austria Pavilion BIO-Europe, Booth 46 See you there!

www.lifescienceaustria.at

Life Science Austria: Advancing life science at the heart of Europe In recent decades, a lively scene of innovative biotechnology companies has put Austria on the European life science map. With their excellent skilled staff and their broad technical and scientific expertise, these companies can play a pivotal role in developing the medicine of the future. In 2012 Austrian 288 biotechnology and pharma companies made more than 10 billion euros in turnover. These companies – from the micro-business with two or three employees to the largescale enterprise with thousands of staff – employ more than 25,000 people. Life Science Austria (LISA) promotes the life science sector in Austria on the international stage and is the first point of call for enquiries relating to it. We

are committed to the development, growth and prosperity of the Austrian life science industries as a leading component of the Austrian economy. In the home market, LISA is a resource for all life science companies within and all companies wishing to relocate to Austria. We see our role in helping companies make connections locally and further afield. We also play a big part in helping new companies get started through our PreSeed – € 200.000 non-refundable – and Seedfinancing – € 1 Mio, refundable when profitable – funding programmes. Every two years, we run a life science business plan competition BOB – Best of Biotech as our way of fostering a culture of excellence.

On the international front, LISA also works towards Austria being a country known worldwide for the excellence of its life science sector. We maintain a regular and high profile presence at leading international life science conferences and exhibitions.

• ecoplus (Lower Austria) • Health Technology Cluster (Upper Austria) • Human Technology Styria (Styria) • LISAvienna (Vienna) • Standortagentur Tirol/Cluster Life Sciences (Tyrol)

Organised through the regional life science clusters, LISA represents companies in the therapeutic, medical technology and diagnostic sectors as well as providers of enabling technologies and related service companies located in the following regional clusters:

Let us know if you want to hear more or have an interest in speaking to a life science business in Austria. LISA is run by Austria Wirtschaftsservice GesmbH (aws) on behalf of the Federal Ministry of Economy, Family and Youth.

For more information on LIFE SCIENCE AUSTRIA contact: Sonja Polan s.polan@awsg.at +43 1 501 75 510 www.lifescienceaustria.at

ABF Pharmaceutical Services GmbH Booth 46 Altmannsdorfer Str 104 A-1120 Vienna T. +43 (0)1 890 120033 M. +43 (0)676 897 115 533 F. +43 (0)1 890 120 011 erich.wirtz@abf-pharma.com www.abf-pharma.com

Contact person Dr. Erich Wirtz, Ph.D.

ABF Pharmaceutical Services – a medium sized global specialist CMO/Central Lab offering labelling, packaging, QP release and distribution of pharma/bio products. Focused services include everything required for getting IMPs to the patient, drug storage across all temperature ranges and

Central Lab services. Renowned for delivering high quality, clients see us as “the right size” CMO/ Central Lab - big enough to successfully manage your large global trial project, but with a personalized flexible service level associated with a smaller nimble organization. Simplify it with ABF!

ACIB GmbH Booth 46 Petersgasse 14 A-8010 Graz T. +43 (0)1 476 548 043 F. +43 (0)1 476 548 039 concetta.giuliani@acib.at www.acib.at

Contact person Dr. Concetta Giuliani, Research Manager

The Austrian Centre of Industrial Biotechnology (acib) is a K2 nonprofit research center based in the cities of Vienna, Graz and Innsbruck. ACIB is a competent partner for research to apply biotechnology in industrial production, focused on biocatalysis, enzymes and (pharmaceutical) protein pro-

duction and purification. acib’s ambitious research programme includes development of new microbial and mammalian expression systems and concepts, extended innovative applications of biocatalysis, and understanding bioproduction on a molecular and genome wide basis.

Activartis Biotech GmbH Booth 46 Contact person Thomas Felzmann, CEO

Activartis develops a dendritic cellbased cancer immune therapy, AV0113. It is individually tailored for each patient’s tumour and is, therefore, in principle applicable for any type of cancer. In a randomised clinical trial for the treat-

Zimmermannplatz 10 A-1090 Vienna T. +43 (0)1 40170 4080 F. +43 (0)1 40170 64080 thomas.felzmann@activartis.com www.activartis.com

ment of brain cancer, significantly improved one-year survival is found as an early trend for efficacy. Activartis seeks a partnership with a pharmaceutical company for late stage clinical development and worldwide market introduction.

AFFiRiS AG Booth 39 Karl-Farkas-Gasse 22 A-1030 Vienna T. +43 (0)1 798 15 75 300 F. +43 (0)1 798 15 75 311 office@affiris.com www.affiris.com

AFFiRiS is an innovative, Vienna based biotechnology company. Using its proprietary AFFITOME® technology, it develops customized peptide-based vaccines, so called AFFITOPES®, to target chronic diseases with attractive markets and unmet medical needs.

Contact person Julia Bock, Communications

Indications include Alzheimer’s disease, Parkinson’s disease, Atherosclerosis, Diabetes and several others. AFFITOPES® mimic the structure of particular natural epitopes in disease targets and are capable of evoking therapeutic antibody responses.

AIT Austrian Institute of Technology Booth 46 Donau-City-Straße 1 A-1220 Vienna T. +43 (0)1 50550 4420 martin.weber@ait.ac.at www.ait.ac.at

Contact person Dr. Martin Weber

The AIT Austrian Institute of Technology is Austria‘s largest nonuniversity research institute with over 1,100 employees. The AIT Health & Environment Department offers expertise in saliva diagnostics: Identification and validation of DNA-methylation and auto-antibody biomarkers,

Technologies to standardize saliva sampling and handling, Bioinformatics for App based data analysis and new workflows, Diagnostic Biosensors using optical, magnetical and nanomaterial-based technologies and Integration of building blocks for saliva-based Point-of-Care devices.

Akron Molecules GmbH Booth 46 Helmut-Qualtinger-Gasse 2 A-1030 Vienna T. +43 (0)1 2360429 office@akron-molecules.com www.akron-molecules.com

Contact person Dr. Henrik Nilsson, CEO

Akron Molecules is a clinical stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics, based on a “drug repurposing“ approach, for the treatment of human diseases with unmet medical need, with a current focus on chronic pain. Akron is currently seeking to raise EUR 7 million in a series B

financing round. Akron’s lead drug candidate, AKR 202, is scheduled to enter a phase II study in pain associated with osteoarthritis in Q4’13 with top-line data expected in Q1’ 15. AKR 202 is a once daily oral product with a favourable safety profile compared to currently approved analgesics.

Anagnostics Bioanalysis GmbH Booth 46

Westbahnstraße 55 A-4300 St. Valentin T. +43 (0)7435 58193 0 F. +43 (0)7435 58193 99 info@anagnostics.com www.anagnostics.com

Contact person Mag. Christoph Reschreiter, CEO

Anagnostics develops systems and tests for multiplex clinical diagnostics especially in the following fields: • Inflammation monitoring (integrated sepsis diagnostics): comprehensive and fast evaluation of inflammation status out of whole blood • detection of pathogens (integ-

rated sepsis diagnostics): comprehensive, fast and sensitive detection of bacteria and fungi • companion diagnostics: cost efficient, sensitive and specific detection of mutations in kras, braf and egfr • drugs of abuse screening: comprehensive, fast and simple out of urine, serum and saliva.

APEIRON Biologics AG Booth 46

Campus Vienna Biocenter 5 A-1030 Vienna T. +43 (0)1 865 65 77 F. +43 (0)1 865 65 77 800 lukas.kadawy@apeiron-biologics.com www.apeiron-biologics.com

Apeiron is a primarily privately financed biotech company in Vienna, developing immunologic and biologic therapies against cancer. Its portfolio consists of five clinical projects and some preclinical approaches. In addition to the lead project APN311 Apeiron develops further clinical projects. APN301 is an immunocytokine and cur-

Contact person Mag. Lukas Kadawy, CFO

rently in a phase II in the US and Canada against neuroblastoma (relapsed/refractory patients) and in a separate trial against melanoma. The recombinant human Angiotensin Converting Enzyme 2 (GSK2586881) was licensed to GlaxoSmithKline in 2010 and is explored in an phase II study in ARDS.

APEPTICO Forschung und Entwicklung Booth 46 Mariahilferstr. 136, Top 1.15 A-1150 Vienna T. +43 (0)664 143 29 19 F. +43 (0)1 2533 033 77 95 b.fischer@apeptico.com www.apeptico.com

Contact person Bernhard Fischer, CEO

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and lifethreatening diseases of the lung. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biophar-

maceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASETM and PEPSCREENTM to significantly reduce cost and to shorten time to market.

Arsanis Biosciences GmbH Booth 46 Contact person Sophie Zettl, PhD, Head of Business Development

Arsanis Biosciences is a biotechnology company dedicated to the development of human antibody based therapeutics against severe infectious diseases. Arsanis is developing a pipeline of monoclonal antibody programs targeting infectious diseases where current approaches are either ineffective or non-existent.

Helmut-Qualtinger-Gasse 2. 1/3. Stock A-1030 Vienna T. +43 (0)1 7990117 F. +43 (0)1 7990117 99 office@arsanis.com www.arsanis.com

Ourâ&#x20AC;&#x2122; lead program, ASN-100, a monoclonal antibody cocktail to prevent and treat severe hospital associated Staphylococcus aureus infections, is in preclinical development. Since its founding in 2010, Arsanis has emerged as a leader in the field of antibody based antiinfectives.

Assign Group Booth 46

Donau-City Strasse 6 A-1220 Vienna T. +43 (0)1 4103 38 05 F. +43 (0)1 4103 38 05 66 info@assigngroup.com www.assigngroup.com

Contact person Anusha Subramaniam, Business Development Manager

Assign is Austria’s largest clinical development organisation. With a reputation for excellence in complex trials, ASSIGN has accumulated expertise through >350 studies, with an emphasis on the therapeutic areas of oncology, vaccines, personalised medicine and orphan diseases. Our experience will help you save valuable

time and budget, allowing you to focus on what you do best. Known as the “right-size” CRO, Assign strikes the perfect balance between its 10+ years of experience & strong Eastern and Western European presence with flexibility & responsiveness, thereby delivering quality and efficiency to your trials.

aws – Austria Wirtschaftsservice GmbH Booth 46 Walcherstraße 11 A A-1020 Vienna T. +43 (0)1 501 75 0 F. +43 (0)1 501 75 900 a.reikerstorfer@awsg.at www.awsg.at

aws is Austria’s national stateowned promotional bank. As a one-stop-shop for business it is set to realize the key objectives of the Austrian government’s economic policies. aws initiatives to support Austrian companies include guarantees and loans. aws is engaged in technology transfer activities, and supports the esta-

Contact person Arnold Reikerstorfer, Angela Siegling

blishment and development of high-tech companies. Focusing on start-up ideas in biotechnology and medical devices, aws provides financial support through two funding programmes: LISA PreSeed (€ 200,000) and LISA Seedfinancing (€ 1 million). More information: www.lifescienceaustria.com; www. preseed.at; www.seedfinancing.at

Baxter Innovations GmbH Booth 46 Industriestraße 67 A-1220 Vienna T. +43 (0)1 20100 247 3006 E-Mail: nadja_spence_simkovsky@baxter.com www.baxter.at

Baxter is Austria‘s largest R&D driven biotech and pharma company. At the same time, Austria is Baxter‘s most important research location for its largest and most R&D intensive department: 80 percent of the product portfolio of the BioScience division are developed and or manufactured here.

Contact person Nadja Spence-Simkovsky

In Vienna, Baxter runs one of the biggest and most efficient plasma fractionation facilities worldwide. It is able to process some 2.3 million liters plasma per year into 18 substances that feed into a broad range of pharmaceuticals of urgent need.

BDS Pharma GmbH Booth 46

Marburger Kai 47 A-8010 Graz T. +43 (0)664 356 03 89 bernd.poecheim@bds-pharma.at www.bds-pharma.at (in construction)

Contact person Bernd Pöcheim, CEO

BDS PHARMA

BDS Pharma GmbH is a drug delivery company. The Company’s mission is to develop and commercialize a novel drug delivery platform combining the use of conventional polymer drug delivery vehicles and approved drugs to be implanted directly within the Central Nervous System. The polymeric delivery devices can provide release of appro-

priate doses of drugs for the given clinical population within the focal site in the brain without causing systemic side effects. Our lead product “Nicaplant” (patent pending) is a brain implant designed to prevent and treat cerebral vasospasm following aneurismal subarachnoid haemorrhage (aSAH) and other brain injuries.

BIA Separations GmbH Booth 46 Contact person Ales Strancar, CEO

BIA Separations manufactures a new generation of proprietary separation (purification) columns that boost productivity and provide cost efficiency in the purification of large biopharmaceuticals. The Convective Interaction Media (CIM®) technology enables the purification of large proteins, plasmid DNA, phages, viral

Europastrasse 8 A-9524 Villach T. +386 (59) 699 500 ales.strancar@biaseparations.com www.biaseparations.com

vaccines and vectors and other large molecules. The technology is fully scalable allowing, to support the separation and purification activities in laboratory based research, QC/QA process controls and industrial scale manufacturing. BIA Separations is also offering Platform industrial purification processes.

Biobank Graz Booth 46

Stiftingtalstrasse 3.1 A-8010 Graz T. +43 (0)316 38572716 F. +43 (0)316 38572731 karine.sargsyan@medunigraz.at www.medunigraz.at/biobank

The Biobank Graz collects various biospecimens and associated data of Styrian probands to support medical research. Samples from selected patients at the University Hospital of Graz, who have signed an informed consent, are stored in different ways for different approaches. This collection contains

Contact person Karine Sargsyan, Leader of Biobank Graz

body fluids like serum (-80°C), formalin fixed paraffin embedded samples as well as cryopreserved tissue samples. This non-profit organisation presents an active scientific partner and supports customers’ by clinical expertise, technology for analyses and organisation.

BIOCRATES Life Sciences AG Booth 46 Eduard-Bodem-Gasse 8 A-6020 Innsbruck T. +43 (0)512 579823 F. +43 (0)512 579823 329 wulf.fischer-knuppertz@biocrates.com www.biocrates.com

BIOCRATES Life Sciences AG offers unique solutions for targeted, quantitative and quality controlled Metabolic Phenotyping (â&#x20AC;&#x153;Deep Phenotypingâ&#x20AC;?). Our mass spectrometry based assays deliver unprecedented accuracy and precision for a comprehensive and predictive understanding of phe-

Contact person Dr. Wulf Fischer-Knuppertz, CEO

notypes and metabolic pathways. Our metabolomics solutions set a new level for standardized data processing, exchange and storage that can readily meet the rigorous demands of various disciplines such as life sciences, personalized medicine, clinical research, and drug development.

Biomay AG Booth 32 Vienna Competence Center Lazarettgasse 19/1 A-1090 Vienna T. +43 (0)1 7966 296 100 F. +43 (0)1 7966 296 222 info@biomay.com www.biomay.com

Contact person Dr. Rainer Henning, CEO

Biomay is a leader in the discovery and development of innovative immunotherapeutics against allergies. Our vaccines are derived from the IgE binding domains of allergens, linked to a highly immunogenic carrier protein. By design, these vaccines lack both IgE dependent early phase and T-cell dependent late phase adverse reaction. The

lead product BM32, a tetravalent grass pollen allergy vaccine, is currently tested in a phase IIb clinical trial. Uniquely, we manufacture our own API in our propriatery GMP-approved plant. We offer excess capacity as a contract manufacturer. Finally, we derive revenue from the sale of research grade recombinant allergens.

Biomedica Medizinprodukte GmbH & Co KG Booth 46

Divischgasse 4 A-1210 Vienna T. +43 (0)1 291 07 56 F. +43 (0)1 290 14 29 bernhard.kueenburg@bmgrp.at www.bmgrp.eu

Contact person Bernhard Küenburg, Managing Director

Biomedica is a leading distribution partner for high value medical products and in vitro diagnostics in the human and veterinary field as well as products for life sciences with subsidiaries in all 13 CEE countries and a team of 250 professionals. Additionally, Biomedica provides innovation in the following areas:

• Biomedica Immunoassays: highly sensitive Elisa test kits for clinical research; • DCX: Surface and room disinfection in hospitals via a dry hydrogenperoxide aersol; • PhC Autoinjectors for intra muscular emergency injection for military and civil use.

BIRD-C GmbH & Co KG Booth 46 Hauptstrasse 88 A-3420 Kritzendorf T. +43 (0)699 1 47654 19 F. +43 (0)2243 28514 alexander.matis@bird-c.at www.bird-c.com

BIRD-C is commercializing a proprietary technology platform entailing empty, non-living bacterial particles generated from Grambacteria (Bacterial Ghosts – BGs) via an innovative, genetically induced, lytic inactivation process. Utilizing this platform technology BIRD-C is developing:

Contact person Alexander Matis, MSc, MBA Business Development

• A portfolio of veterinary vaccines licensed to a major US veterinary pharmaceutical company in January 2012; • An innovative treatment for inflammatory bowel disease in collaboration with a German pharmaceutical company; • A novel melanoma vaccine based on genetically modified BGs.

Boehringer Ingelheim Biopharmaceuticals GmbH Booth 36 Binger Straße 173 D-55216 Ingelheim am Rhein T. +49 (6132) 77 90506 F. +49 (6132) 77 98287 pauline_eva.bronzel@boehringer-ingelheim.com www.bioxcellence.com

As a leading biopharmaceutical contract manufacturer Boehringer Ingelheim BioXcellenceTM offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production

Contact person Pauline Bronzel, Marketing Management

technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellenceTM makes outsourcing easy.

BOKU – University of Natural Resources and Life Sciences Booth 45 Gregor Mendel Straße 33 A-1180 Vienna T.+43 (0)1 47654 1015 F. +43 (0)1 47654 2603 bernhard.koch@boku.ac.at www.boku.ac.at

Contact person Bernhard Koch, Techtransfermanager

As a university of life sciences, BOKU assumes important social and political responsibilities. Its core competency is the research and communication of ways of sustainable use and the protection of natural resources. The interdisciplinary approach in research

results in numerous rewarding inventions and publications especially in the field of Biotech and Agrobiotech. Moreover in recent years, several successful spin-offs were founded at BOKU, especially in the Bio-Science enviroment (e.g. Polymun, f-star, Evercyte)

Campus Science Support Facilities, CSF Vienna Booth 45

Dr. Bohr-Gasse 3 A-1030 Vienna T. +43 (0)664 808477030 andreas.sommer@csf.ac.at www.csf.ac.at

Contact person Andreas Sommer, Head of NGS Facility

The CSF NGS facility is Austria‘s most experienced next generation sequencing provider using Illumina‘s HiSeq systems to deliver outstanding throughput and service quality. Services include the preparation of libraries, sequencing of samples deriving from a

variety of applications and bioinformatic support. The CSF Bioinformatics and Scientific Computing facility (BioComp) provides unique expertise and services in the areas of bioinformatics and scientific computing to academic and industrial researchers.

CBC Capricorn Biotech Consulting e.U. Booth 46 Untere Weißgerberstraße 49/19 A-1030 Vienna T. +43 (0)676 930 3370 martin.goetting@cbcmg.com www.capricorn-biotech-consulting.com

CBC Capricorn Biotech Consulting provides services in the field of business development, strategic partnering, commercial operations and funding for small to medium sized firms in the life science sector. This could be biotech firms with a focus on, but not limited to, vaccines and antibodies as well as diagnostic or medical device companies.

Contact person Martin Götting, General Manager

Foci for the attendance of the present Bio-Europe are: • Novel Vaccine Adjuvant and Delivery Platform: Strategic Partnering for ViscoGel, Sweden; • Novel Cancer Biomarker CA IX: Market Exploration for BioScience, Slovakia; • Present the services of CBC to potential clients.

CeMM Reserach Center for Molecular Medicine Booth 45 AKH BT 25.3 Lazarettgasse 14 A-1090 Vienna T. +43 (0)1 40160 70011 F. +43 (0)1 40160 970 000 office@cemm.oeaw.ac.at www.cemm.at

Contact person Stefan Kubicek, Sebastian Nijman, Group Leaders at CeMM

CeMM is an international, independent and interdisciplinary research center in Molecular Medicine, situated on the campus of the Medical University and the General Hospital in Vienna. Driven by medical needs, CeMM integrates basic research and clinical expertise to pursue innovative diagnostic

and therapeutic approaches. 13 groups with about 150 scientists focus on cancer, inflammation and immune disorders. CeMM aims to assist in preparing the predictive, preventive and personalized medicine of the future, and to train a new generation of researchers in molecular medicine.

CSC Pharmaceuticals Booth 46 GewerbestraĂ&#x;e 18-20 A-2102 Bisamberg T. +43 (0)2262 6060 F. +43 (0)2262 606 300 office@csc-pharma.com www.csc-pharma.at

Contact person Dr. Gerda Achzet, Licensing Manager CEE

CSC Pharmaceuticals, as part of the international Angelini group with 3.600 employees worldwide, operates regionally, mainly in Central & Eastern Europe. Our mission is to meet customersâ&#x20AC;&#x2122; day-to-day needs with effective, reliable and high-quality pharmaceuticals. Our

product range grows continuously to encounter the emerging needs of hospital, Rx and OTC markets by focusing on four main therapeutic areas, which are: pain relief, neuropsychiatry, oral care, and gynecology.

Dutalys GmbH Booth 46

Muthgasse 11/2, 3.OG A-1190 Vienna T. +43 (0)1 9971832 F. +43 (0)1 99718321 roland.beckmann@dutalys.com www.dutalys.com

Contact person Dr. Roland Beckmann, CSO

Dutalys is a private, Austrian antibody technology company committed to developing superior treatments for complex and multifactorial diseases, including cancers and inflammatory diseases. Dutalys has built the DutaMab™ platform technology to provide the only class of bispecific anti-

body molecules that retain all the advantages of state-of-the-art monospecific antibody therapeutics. The benefits of DutaMabs™ include high affinity against all classes of drug targets, convenient manufacturing fully equivalent to monospecific antibody drugs, and outstanding stability.

ecoplus. The Business Agency of Lower Austria Booth 46 Magnesitstraße 1 A-3500 Krems T. +43 (0)664 612 69 48 F. +43 (0)2732 87470 70 v.ossmann@ecoplus.at www.ecoplus.at

ecoplus, the business agency of Lower Austria in the centre of Europe acts as interface between business and politics, companies and authorities, investors and initiators of regional projects on both a national and international scale. ecoplus offers tailored services, information and support to companies, project backers and partners in areas such as:

Contact person Verena Ossmann

• Establishment or expansion of companies; • Provision of attractive company locations; • Facilitation of access to educational and R&D facilities; • Intercompany cooperation and networks; • Initiatives involving market activities in the new Europe.

EUCODIS Bioscience GmbH Booth 46 Campus Vienna Biocenter II Viehmarktgasse 2a/2 OG A-1030 Vienna T. +43 (0)1 890 080 410 F. +43 (0)1 89080311 office@eucodis.com www.eucodis.com

Contact person Dr. Susanne Bach, Key Account Manager

EUCODIS Bioscience is an application-driven enzyme engineering and manufacturing company. We offer high-performance enzymes for biopharma, fine chemicals, cosmetics industry: over 50 enzymes like betalactamases, lipases, catalases and others, which are selected to include the desired

properties, i.e. chiral and regioselectivity, broader temperature- and pH-profiles. We engineer enzymes according to our customersâ&#x20AC;&#x2122; requirements, using our proprietary mutagenesis and recombination toolbox. We provide customized services in recombinant protein and enzyme production.

Evercyte GmbH Booth 46

Contact person Otto Kanzler, CEO and co-founder Johannes Grillari, CSO and co-founder

Evercyte is a provider of relevant preclinical model systems that will allow for acceleration of drug discovery and development by reduction of development time and cost. These cellular model systems are based on primary cells that are immortalized without altering key functional characte-

Muthgasse 18, A-1190 Vienna +43 (0)699 18162222 (scientific issues) +43 (0)664 4227861 (business issues) otto.kanzler@evercyte.com johannes.grillari@evercyte.com www.evercyte.com

ristics or by using adult stem cells and urine-derived, induced pluripotent stem cells. Evercyte offers immortalized cell lines and panels of different tissues, cell culture media and the development of customer-tailored cell based assays and cells for preclinical target- and drug research.

F4 Pharma i.G. Booth 46

Bürgerspitalgasse 24/10 A-1060 Vienna T. +41 79 788 1800 petra.wuelfroth@accella-advisors.com www.F4-Pharma.com

Contact person Dr. Petra Wülfroth, CEO (designated)

F4 Pharma i.G. is a development stage bio-pharmaceutical company established 2013 in Vienna. The core product is FX06 – a peptide with high potential in indications associated with vascular leakage. Development will be concentrated on two indications (1.) vasoplegic syndrome – a certain form

of circulatory shock and (2.) kidney transplantation. Solid preclinical and clinical data are available and warrant a direct start in ph II. Human data from ph I and ph IIa studies proofed a favorable safety profile, excellent tolerability and transferability of results from animal models to men.

FFG – Austrian Research Promotion Agency Booth 46 Sensengasse 1 A-1090 Vienna T. +43 (0)5 7755 0 F. +43 (0)5 7755 97900 office@ffg.at www.ffg.at

The Austrian Research Promotion Agency (FFG) is the national funding institution for applied research and development in Austria. We offer a comprehensive range of services for Austrian enterprises, research institutions and researchers – from the management of public funding programmes to

Contact person Dr. Astrid Hoebertz, Project Manager

consulting services in all phases of technology development and innovation, from support for integration into European research programmes and networks to the promotion of Austria“s interests at the European and the international level.

FH Campus Vienna – University of Applied Sciences Booth 45 Helmut-Qualtinger-Gasse 2 A-1030 Vienna T. +43 (0)1 6066877 3511 F. +43 (0)1 6066877 3509 thomas.czerny@fh-campuswien.ac.at www.fh-campuswien.ac.at

The Division of Molecular Biotechnology is part of the University of Applied Sciences, FH Campus Vienna. Our research activities cover two separate areas. In a focus on signaling pathways we generate reporter systems to study the cellular activities of the heat shock pathway and the Wnt pathway

Contact person Dr. Thomas Czerny, Research Molecular Biotechnology

for drug development. In a second focus on allergy research we develop tools for improved diagnosis and treatment of food allergies. In addition, we investigate pathomechanisms underlying respiratory allergies for identification therapeutic targets.

Greiner Bio One Booth 46

Gewerbepark 2 A-4261 Rainbach T. +43 (0)664 88 41 06 75 max.sonnleitner@gbo.com www.gbo.com

Contact person Dr. Max Sonnleitner, Business Development, Area Manager GENSPEED

A subsidiary of Greiner Bio-One – Lambda – is a biotech company that develops and produces molecular diagnostic solutions for the detection of pathogens (viruses and bacteria) from various specimens. Further fields of research and development include food diagnostics and quality control pro-

ducts for the pharmaceutical industry. With the novel GENSPEED® Test System we developed a molecular diagnostics platform that for the first time enables simple, rapid and simultaneous detection of up to 8 parameters from various specimens.

Haplogen GmbH Booth 46

Campus Vienna Biocenter 5 A-1030 Vienna T. +43 (0)1 916 55 22 10 F. +43 (0)1 916 55 22 16 office@haplogen.com www.haplogen.com

Contact person Dr. Georg Casari, CEO

Haplogen is a privately held biotechnology company based on an entirely novel genetics technology platform. Its goal is to combat infectious diseases. Despite improved hygiene and successful vaccination programs, infectious diseases remain a major cause of morbidity and mortality.

Emerging resistance to conventional drugs and a lack of scientific tools further add to this immense medical and socio-economic problem. Our mission is to identify novel pathogen host factors using our proprietary technology and thereby develop therapeutics to treat infectious diseases.

Health Technology Cluster Booth 46 HafenstraĂ&#x;e 47-51 A-4020 Linz T. +43 (0)732 79810 5151 F. +43 (0)732 79810 5150 philipp.wittmann@clusterland.at www.gesundheits-cluster.at

The Health Technology Cluster is a network for increasing innovative capacity and international competitiveness of Health Technology companies, their suppliers as well as relevant research and healthcare facilities. The cluster currently connects 220 partner companies from Austria and South Germa-

Contact person DI (FH) Philipp Wittmann, Cluster Manager

ny. Due to the Upper Austrian strength in medical technology, the main focus is on medical electronics, software, clean room & hygiene, hospital equipment, enduser products, diagnostics-pharma and materials. More detailed information under www.gesundheits-cluster.at

Hookipa Biotech AG Booth 46 Helmut-Qualtinger-Gasse 2 A-1030 Vienna T. +43 (0)1 890 63 60 F. +43 (0)1 890 63 60 399 office@hookipabiotech.com www.hookipabiotech.com

Contact person Dr. Katherine Cohen, CEO

Hookipa Biotech develops a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology, which is a novel vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious

diseases and cancer. The platform is one of the most promising new technologies for next generation vaccines due to its ability to stimulate both potent B-cell and CD8+ T-cell immune responses. Vaxwave® has been validated in various disease models.

Human.technology Styria GmbH Booth 46 Reininghausstraße 13 A-8020 Graz T. +43 (0)316 587016 F. +43 (0)316 587016 16 office@human.technology.at www.humantechnology.at

Contact person Dr. Robert Gfrerer, CEO

Human.technology Styria is a membership organization for life science & related industries in Austria, a powerhouse of innovation in the following fields: • Biobanking and biomarker technologies • Process engineering for pharmaceutical and biotechnology companies

• Advanced biomedical sensor technologies The Cluster has assembled a highly integrated network of life science companies across Styria including start-ups right up to industry flagships. This hotbed of business development backed by world class science ensures that companies in Styria have that edge for success.

IMBA Institute of Molecular Biotechnology GmbH Booth 45 Contact person Dipl. Kfm. Michael Krebs, Managing Director

IMBA â&#x20AC;&#x201C; Institute of Molecular Biotechnology is one of the leading biomedical research institutes in Europe focusing on cutting-edge functional genomics and stem cell technologies. The major research fields are: Disease modeling and mouse genetics, stem cell and RNA biology. IMBA is located at the Campus Vienna Biocenter,

Dr. Bohr-Gasse 3 A-1030 Vienna T. +43 (0)1 79044 4400 F. +43 (0)1 79044 4401 michael.krebs@imba.oeaw.ac.at www.imba.oeaw.ac.at

the vibrant cluster of universities, research institutes, and biotech companies in Austria. With almost 200 employees and an annual research budget of around 25 million, IMBA is the largest research unit of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research.

in-spectum Booth 46

Kupelwiesergasse 5 A-1130 Vienna T. +43 (0)664 1010079 F. +43 (0)1 876 0715 elisaweta.bubits@in-spectum.com www.in-spectum.com

in-spectum e.U. offers Executive Search and Consulting Services. The expertise of in-spectum covers Direct Searches for national, regional and Headquarter functions such as General and Regional Manager roles, Head of Corporate Affairs, Regulatory Affairs, BD, IP, M&S, Medical, R&D, Operations,

Contact person Elisaweta Bubits, Owner

Preclinical Facilities for Human and Animal Healthcare, Biotechnology and Research Institutions. The services of in-spectum include Career Consulting and Systemic Coaching in German, English, French and Bulgarian language and focus on the individual needs of the Clients.

INiTS Universitäres Gründerservice Wien GmbH Booth 45 Graumanngasse 7/Stiege B A-1150 Vienna T. +43 (0)1 715 72 67 0 F. +43 (0)1 715 72 67 25 office@inits.at www.inits.at

Contact person Dr. Irene Fialka, CEO

INiTS is a business incubator designed to improve the rate of startup success in Vienna by helping young entrepreneurs conceive, launch and grow the next great company. During our program, startups receive funding, handson support, resources, a network

and an office space to bring them to the next level. The program is aimed at bright and ambitious graduates, staff and students of the Vienna universities and technical colleges with great ideas.

Innovacell Biotechnologie AG Booth 46 Mitterweg 24 A-6020 Innsbruck T. +43 (0)512 573680 F. +43 (0)512 573680 5 ekkehart.steinhuber@innovacell.com www.innovacell.com

Contact person Ekkehart Steinhuber, CEO

Innovacell Biotechnologie AG is a privately-held Phase III biotechnology company based in Innsbruck, Austria. The company is engaged in the clinical development and commercialization of autologous (i.e. patient’s own cells), minimally invasive cell therapies.

Innovacell’s personalized products are potentially curative one-off treatments, which re-establish functionality of sphincter muscles in patients, e.g. with stress urinary incontinence (SUI) or faecal incontinence (FI).

INOXIA Lifesciences GmbH Booth 46

Erlgasse 48 A-1120 Vienna T. +43 (0)1 810 53 66 F. +43 (0)1 810 53 66 13 akubin@inoxia.at www.inoxia.at

Contact person Dr. Andreas Kubin, CEO

INOXIA is an innovative newly founded Viennese Biotech Company which specializes in the field of drug development, with human peroxidases as the main target. Peroxidases are innate immune system enzymes, and are responsible for chronic inflammatory and neurodegenerative diseases.

Selective potential inhibitors form the basis for new medication, to be used for the treatment of Asthma, COPD, Endometriosis and bowel diseases such as Crohn´s disease and Ulcerative colitis, to mention a few. The company is developing small molecule candidates for entry into clinical trials.

Lifesciences

Joanneum Research Booth 46 Elisabethstrasse 5 A-8010 Graz T. +43 (0)316 876 4000 F. +43 (0)316 8769 4000 health@joanneum.at www.joanneum.at/health

Our central activity is innovative applied research that bridges the gap between basic research and applications. Working according to high international quality standards (GLP, EN ISO 13485), we are a valued partner for the pharmaceutical R&D and pharmaceutical and medical device industries. We offer services in these areas:

Contact person Dr. Frank Sinner, Deputy Director of Institute

• Pharmacokinetics/pharma codynamics / bioequivalence; • Biological and pharmaceutical analysis; • Metabolomics; • Health economics & outcome research; • Medical device development & evaluation.

Kliment & Henhapel PatentanwĂ¤lte OG Booth 46 Singerstrasse 8/9 A-1010 Vienna T. +43 (0)1 512 77 91 F. +43 (0)1 512 47 15 office@klimenthenhapel.at www.klimenthenhapel.at

wien | linz | salzburg

Contact person Dr. Andreas PfĂśstl, Patent Attorney

We are a Patent Law Office with Headquarters in Vienna and Branch Offices in Linz and Salzburg. Our office offers expertise in all technical fields which enables us to provide patent prosecution services with no restriction to our clients.

Additionally we are experienced in patent litigation matters not only in Austria but also with international orientation. Trademarks and Designs matters complete our services that we are able to offer to our clients.

Lacerta Technologies GmbH Booth 46 Dr. Karl-Dorrek-Str. 23-29 A-3500 Krems an der Donau T. +43 (0)664 883 16205 F. +43 (0)664 77 88316206 zsombor.lacza@lacertatech.com www.lacertatechnologies.com

Contact person Zsombor Lacza, MD, PhD

Lacerta Technologies is a regenerative medicine company located in Krems, Austria which targets to translate research results into products for clinical use. Lacerta aims to develop new solutions for patients who suffer bone loss by facilitating complete bone recovery. To reach this goal Lacerta

is focusing on the development of a unique bone graft technology which is capable to accelerate bone healing as well as a custommade bone graft system creating personalized bone graft coatings for specialized clinics and tissue banks.

Ludwig Boltzmann Gesellschaft Booth 45 Contact person Peter Mayrhofer, Senior Manager Medical & Life Sciences Univ. Prof. DI Dr. Heinz Redl, Director Ludwig Boltzmann Institute for Experimental and Clinical Traumatology

The Ludwig Boltzmann Gesellschaft (LBG) is a non-university research organization based in Vienna, operating research institutes (Ludwig Boltzmann Institutes) in the fields of medicine / life sciences as well as the humanities, social-

Nußdorfer Straße 64 A-1090 Vienna T. +43 (0)1 513 27 50 29 F. +43 (0)1 513 23 10 office@lbg.ac.at www.lbg.ac.at

and cultural sciences. The LBG initiates the collaboration between academic and company partners to pursue innovative translational research projects and to bridge the gap between basic research and application.

LifeScience Vienna Muthgasse Booth 46 Weyringergasse 34/2 A-1040 Vienna T. +43 (0)699 17131621 F. +43 (0)1 3064306 44 office@lifescience-vienna.at www.lifescience-vienna.at

LifeScience Vienna Muthgasse Vienna‘s new Innovation Center for Research & Teaching in the 19th district. Infrastructure requirements for different fields of research such as Biology, chemistry and physics – up to level S3. More than 21,000 square metres of office and lab space is already in use. (University

Contact person Mehrdokht Tesar, PR & Marketing

of Natural Resources and Life Sciences (BOKU), companies & organisations) Next buildings: BioTech II 28,900 m2 of flexible and state-ofthe-art laboratories & offices. 203 parking spaces White Space 25,355 m2 and 340 parking spaces

LISAvienna Booth 45,46 Walcherstraße 11A A-1020 Vienna T. +43 (0)1 501 75 358 F. +43 (0)1 501 75 492 office@LISAvienna.at www.LISAvienna.at

Contact person Jürgen Fuchs, Clustermanager Biotech/Pharma

LISAvienna - Life Science Austria Vienna is the life science cluster organization of the City of Vienna, serving all stakeholders in the areas of biotechnology/pharmaceuticals and medical technology. As a joint initiative of the Republic of Austria and the City of Vienna, LISAvienna helps to ensure that

the economic potential of life sciences is put to good use and turned into marketable products, improved processes and new services. The main focus of its activities is on custom-tailored advice and assistance for innovative enterprises.

Marinomed Biotechnologie GmbH Booth 46 Veterinärplatz 1 A-1210 Vienna T. +43 (0)1 25077 4460 F. +43 (0)1 25077 4493 johanna.uhlmann@marinomed.com www.marinomed.com

Contact person Mag. Johanna Uhlmann, Head Business Development

Marinomed Biotechnologie GmbH is a biopharmaceutical development company focusing on the development of innovative therapies against respiratory diseases (as common cold and influenza) based on an innovative anti-viral respiratory technology platform called mavirex. In addition, Mari-

nomed develops pharmaceuticals in type I allergy, and autoimmune diseases. Safety and effectiveness of the mavirex platform have been proven in three clinical trials in adults and children and by its marketed anti-viral OTC common cold and influenza portfolio.

Matschnig & Forsthuber OG Patentanwaltskanzlei Booth 46 Siebensterngasse 54 A-1070 Vienna T. +43 (0)1 5233496 F. +43 (0)1 5264886 gufler@matschnig-patent.at www.matschnig-patent.at

Contact person Dr. Petra Gufler, European Patent Attorney

Patentanwaltskanzlei Matschnig & Forsthuber has been operating for 30 years on a national and international level in all fields of intellectual property rights. The firmâ&#x20AC;&#x2DC;s services include professional support and representation of patents, trademarks, designs and other industrial property rights as

well as consulting in all aspects of intellectual property. Our team of legally trained academics with technical and scientific background covers a wide range of disciplines including physics, mechanical engineering, electronics, telecommunications, chemistry and life sciences.

Medical University of Graz Booth 46 Auenbruggerplatz 2 A-8036 Graz T. +43 (0)316 385 72018 F. +43 (0)316 385 72030 verwertung@medunigraz.at www.medunigraz.at

The core competencies of the Medical University of Graz are high standard education, research at an international level, and the continuous improvement of topquality medicine. In the immediate vicinity of the university hospital the Center for Medical Research (ZMF) and the

Contact person Dr. Heidi Schmitt, Technology Transfer

large Biobank Graz offer ultramodern infrastructure and knowhow for projects with scientific and corporate partners. Committed researchers from all areas of medicine perform high-ranking research and engage in cooperative research projects as well as significant clinical studies.

Medical University of Vienna Booth 45 Spitalgasse 23 A-1090 Vienna T. +43 (0)1 40160 25203 F. +43 (0)1 40160 910000 technologietransfer@meduniwien.ac.at www.meduniwien.ac.at

Contact person Dr. Claudia Ballaun, IPR Managerin Univ.Doz. Dr. Andrea Kolbus, IPR Managerin

The Medical University of Vienna (MedUni Vienna) is one of Europe’s medical training and research facilities with the greatest history and tradition. Counting almost 7,500 students, it is today the largest medical training facility in the German-speaking region. With

its 31 university departments, 12 medical-theoretical centres and numerous highly specialised laboratories, it also ranks amongst the most significant cutting-edge research institutions in Europe in the biomedical sector.

Mucokinetica Booth 46 Schiffmühlenstrasse 47 / 330 A-1220 Vienna T. +44 (0)7774 121180 rod.hall@mucokinetica.com www.mucokinetica.com

Contact person Dr. Rod Hall, CEO and Chief Scientific Officer

• • •

Epithelial biology drug discovery & development company Lead product is an Orphan Drug treatment for Cystic Fibrosis with enhanced pharmacological profile compared to existing treatments Long duration reduction of

• •

excessive sodium absorption in the airways; and long duration increased ciliary transport of secretions PreSeed funding support from AWS Seeking funding for pre-clinical and early clinical development

Nabriva Therapeutics AG Booth 46

Leberstrasse 20 A-1110 Vienna T. +43 (0)1 74093 1240 petra.taylor@nabriva.com www.nabriva.com

Contact person Ralf Schmid, CEO

Nabriva specializes in developing pleuromutilins, a new class of antibiotics in humans, to treat severe bacterial infections, an unmet medical need. BC-3781, the lead product (Phase 3 ready), is a broad spectrum agent for treating complicated skin infections (cSSSI) and pneumonia caused by resistant

bacteria. Proof of concept for the systemic use in human was achieved in a Phase 2 trial in patients with cSSSI. BC-7013 is in Phase 1 development for topical treatment of bacterial infections. Pleuromutilins broadening Gramnegative coverage are the latest addition to the portfolio.

OncoQR ML OG Booth 46 Walterstrasse 21 A-3011 Tullnerbach T. +43 (0)664 516 00 32 c.langer@oncoqr.com

OncoQR ML is a new Austrian biotech company founded 2012 by two seasoned pharma professionals, Dr. Geert Mudde and Christof Langer, MSc, MBA. OncoQR aims to develop, produce, and market biological drugs against oncological diseases. OncoQRâ&#x20AC;&#x2122;s first product (OQR100) is directed against gastro-intestinal (pancreatic) cancer.

Contact person DI. Christof Langer, MBA, CEO

The drug concept is based on the potential of a proprietory S-TIRâ&#x201E;˘ platform, which allows reversible treatment by either starving of tumor cells and/or tumor cell death due to cytotoxic T cells, CMC (complement mediated cytotoxicity), and ADCC (antibody dependant cellular cytotoxicity).

Origimm e.U. Booth 46 Leberstrasse 20 A-1110 Vienna T. +43 (0)676 448 4825 sselak@origimm.com www.origimm.com

Contact person Dr. Sanja Selak, Founder and CSO

Origimm is a young ambitious Austrian biotech company striving to become a market leader in protective antigen discovery. Using its proprietary ProVaDis速 technology platform Origimm supplies its candidates to industry pipelines for innovative vaccine and immune therapy development.

Origimm discovers most effective antigen candidates for the 1st pathogen specific therapeutic vaccine for treatment of acne vulgaris. Origimm is proactively looking for partnerships with academics and industry players to define and run further antigen discovery programs on a demand driven way.

Ortner Reinraumtechnik GmbH Booth 46 Uferweg 7 A-9500 Villach T. +43 (0)4242 311 660 F. +43 (0)4242 311 660 4 reinraum@ortner-group.at www.ortner-group.com

Contact person Stefanie Rud, Vice President

As equipment and systems manufacturer for cleanroom requirements in the life science industry, the Ortner group offers a selected product range for creating cleanness. The company has positioned

itself as a systems supplier for locks and decontamination processes. Accordingly, Ortner creates clean and high-quality production environments to ensure secure end products for their customers.

Panoptes Pharma GmbH Booth 46

Parkring 10 A-1010 Vienna T. +43 (0)664 8557369 franz.obermayr@panoptes-pharma.com www.panoptes-pharma.com

Contact person Dr. Franz Obermayr, CEO

Panoptes is a privately held biotech company focusing on developing small molecule therapies for the treatment of severe eye diseases with high unmet need. The development of clinical candidate PP-001 focuses on autoimmune uveitis. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which

to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications. We believe the combination of our technology and cost-efficient development strategy will help ensure a rapid and more predictable path to commercialization.

PDC Biotech GmbH Booth 46 Kaerntner Ring 10/12 A-1010 Vienna T. +43 (0)1 890 0077 10 F. +43 (0)1 890 3518 10 office@pdcbiotech.com www.pdcbiotech.com

PDC Biotech (PDC) is developing a proprietary series of prostaglandin F2 receptor antagonists for the treatment of preterm labour and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. PDC has successfully completed the first-in-human clinical trial for its

Contact person Roman GĂśtz, Managing Director

lead compound PDC31. This study was designed to evaluate safety as well as provide proof of concept for the ability to inhibit excessive uterine contractility. The companyâ&#x20AC;&#x2122;s immediate goal is to continue development of its lead program to proof of concept in pregnant women.

pharm-analyt Labor GmbH Booth 46 Ferdinand-Pichler-Gasse 2 A-2500 Baden T. +43 (0)664 5160842 F. +43 (0)2252 490509 info@pharm-analyt.com www.pharm-analyt.com

Contact person Martin van Dam, Director Business Development

Class-Leading Service Provider & CRO for Bioanalysis. GLP and GMP certified, escorting clinical phases I-III, preclinical and early stage investigation. QUANTIFICATION: Assay development and validation for substances in plasma / urine / tissue with extremely high sensitivity (e.g. 250 fg/mL plasma). IDENTIFICATION: Structure eluci-

dation of unknown peaks: Metabolite profiling, impurities, degradation products INVESTIGATION • Bioanalytical feasibilities • Tissue analysis • Trouble shooting BIOMARKERS: Discovery of biomarkers in plasma: Small Molecules & Peptides, Several Patents

Polymun GmbH Booth 46 Donaustr. 99 A-3400 Klosterneuburg T. +43 (0)2243 25060 300 F. +43 (0)2243 25060 399 office@polymun.com www.polymun.com

Contact person Dr. Dietmar Katinger, CEO

Polymun is a privately held CMO near Vienna, Austria, founded in 1992. Our core activities are contract development and manufacturing of biopharmaceuticals (mammalian and microbial expression systems) as well as liposomal formulations. Polymun operates in accordance with GMP guidelines and holds an Austrian

production license thus meeting all EU requirements for drug manufacturing (last inspection June 2013). Polymun employs a team of more than 50 highly qualified scientists, technologists and support staff. We are a flexible partner focused on the requirements of our clients.

Quintiles Booth 46 Stella-Klein-LĂśw-Weg 15 A-1020 Vienna T. +43 (0)664 5337014 www.quintiles.com

Contact person Dr. Nora Gedeon, Director Global Sales

Quintiles (NYSE: Q) is the worldâ&#x20AC;&#x2122;s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our

service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Recardio GmbH Booth 46 Lakeside B07b A-9020 Klagenfurt T. +43 (0)463 210 131 F. +43 (0)463 210 131 info@recardio.eu www.recardio.eu

RECARDIO (REgenerative CARDIOvascular Therapy) is an innovative, Klagenfurt based life science company founded in 2011. It is focusing on regenerative therapeutic modalities for the treatment of cardiovascular diseases. After establishing proof-of-principle in vivo

Contact person Dr. Roman Schenk, CEO

and the completion of its preclinical development, it is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life and survival.

REDL Life Science Patent Attorneys Booth 46 Donau-City-StraĂ&#x;e 1 A-1220 Vienna T. +43 (0)1 20501 47100 F. +43 (0)1 20501 47900 office@redlpatent.com www.redlpatent.com

Contact person Dr. Gerda Redl, Patent and Trademark Attorney, European Patent Attorney Dr. Manuela Loidl, European Patent Attorney

The life science industry. Exciting ideas. Huge potential. You attract partners. Negotiate deals. Stay ahead of the competition. When it comes to patents, we mean business. REDL Life Science Patent Attorneys is an IP law firm with a team of specialists in the area of Life Science. At REDL Life Science Patent Attorneys, we are com-

mitted to protecting your most valuable assets. We obtain commercially valuable patents and other IP rights for your products and technologies. We assess the strength of patents during licensing or financing negotiations. We assert your rights in case of conflicts. Our primary goal is to support your business.

roombiotic Booth 46

Contact person Stefan Liebminger, Founder, R&D

[roombiotic] probiotic solutions

Petersgasse 12 A-8010 Graz T. +43 (0)316 873 8814 F. +43 (0)316 873 8819 stefan.liebminger@tugraz.at http://sciencepark.at/unsere-firmen/448/roombiotic

roombiotic is developing decontamination technologies based on airborne antimicrobial substances. These small molecules belong to secondary metabolites which are involved in the signal transduction of microorganisms. The company is specialized on the identification of novel antimicrobial substances

from natural occurring microbial antagonists. The main focus is a residue-free decontamination of complex surfaces and microstructures with biogenic substances. This technology is suitable for use in the food industry to minimize the loss of quality along the value chain.

S-TARget therapeutics GmbH Booth 46 Mooslackengasse 17 A-1190 Vienna T. +43 (0)69918904206 geert.mudde@s-target.com www.s-target.com

Contact person Dr. Geert C. Mudde

S-TARget therapeutics develops human specific therapeutic vaccines to cure and prevent severe allergic diseases, based on the proprietary S-TIRtm technology platform. S-TARget’s therapies are not limited by the patient’s IgE levels. SG100, S-TARget‘s 1st clinical candidate against house dust mite

(HDM) induced allergic asthma, recently achieved in vivo PoC in phase 1 and 2 like clinical studies with non human primates suffering from this disease. Both HDM induced early and metacholin induced late phase reactions were significantly improved in treated animals versus placebo controls.

Sandoz GmbH Booth 46 Biochemiestrasse 10 A-6250 Kundl T. +43 (0)664 8271441 F. + 43 (0)5338-200442 bernhard.siebold@sandoz.com www.sandoz.com

The Biopharmaceuticals unit at Sandoz GmbH, an international pharmaceutical company (2012 sales: US$ 8,7 bn), is focusing on biosimilar products as well as on biotech cooperations with Third Parties. Based on many years of experience in recombinant microbial and mammalian cell culture produc-

Contact person Dr. Bernhard Siebold, Manager Biotech Cooperations

tion at commercial scale, Sandoz is in the position to provide cGMP manufacture of products for clinical trials and commercial supply. Sandoz offers production of recombinant proteins in 1,300L up to 40,000L fermenters comprising corresponding purification lines in multipurpose facilities in Austria.

Sanochemia Pharmazeutika AG Booth 46 Boltzmanngasse 11 A-1090 Vienna T. +43 (0)1 319 14 56 324 F. +43 (0)1 319 14 56 316 k.gerdes@sanochemia.at www.sanochemia.at

Contact person Dr. Klaus Gerdes, CMO/COO

Sanochemia Pharmazeutika AG is an internationally active specialty pharmaceuticals company with a long track record in the development and production of human pharmaceuticals, diagnostics and veterinary drugs. The Company specializes in segments of the oncology, neurodegeneration and,

in particular, imaging diagnostic markets. Currently the core focus is on the development of efficient cancer diagnostics such as VidonÂŽ, a photodynamic diagnostic agent for improved detection of bladder cancer, and SecreluxÂŽ, a pancreatic function diagnostic agent.

Sanova Pharma Booth 46 Contact person Alexander Burstein, Director Business Development

Sanova Pharma is the leading distributor who cares for the marketing, sales and logistics of foreign companiesâ&#x20AC;&#x2122; products in Austria. Thus we make YOUR products a success! Sanova addresses both medical doctors and pharmacies. In the RX business we target GPs, gastroenterologists, endocrinologists,

Haidestrasse 4 A-1110 Vienna T. +43 (0)1 80104 2521 F. +43 (0)1 80104 9382 alexander.burstein@sanova.at www.sanova.at

ENT doctors and other disciplines, depending from the current focus. In the OTC business leading products in the field of cough & cold, gastro-intestinal disorders, nail fungus, etc. make us no. 2 in Austria. Come and talk to us, Sanova will be happy to sell your products in Austria.

Savira pharmaceuticals GmbH Booth 46 Veterinärplatz 1, Building IA A-1210 Vienna T. +43 (0)1 25077 5904 F. +43 (0)1 25077 5999 oliver.szolar@savira.at www.savira.at

Contact person Dr. Oliver Szolar, CEO

Savira focuses on next generation influenza therapeutics. Our main project is the rational, structurebased design of inhibitors impeding the cap-snatching mechanism of the influenza polymerase eventually preventing the virus from hijacking the protein-production machinery of the infected cell.

2012 Savira signed an exclusive license and collaboration agreement with Roche. Savira and Roche have formed a strong and effective R&D team, further backed by renowned scientists from the EMBL – one of Savira’s main shareholders.

Standortagentur Tirol Booth 46 Ing.-Etzel-Straße 17 A-6020 Innsbruck T. +43 (0)512 576262-48 F. +43 (0)512 576262-10 petra.stoeckl@standort-tirol.at www.standort-tirol.at

Part of the “Standortagentur Tirol”, the cluster management platform brings together topclass Tirolean research institutions from the life sciences sector with active companies located in the region. It imparts expertise, provides thematic impetus, offers links to specialist partners, en-

Contact person DDR. Petra Stöckl, Clustermanager Life Sience Tirol

courages and supports interdisciplinary collaborations and R&D partnerships, thereby boosting innovation performance in the region and promoting enhanced competitiveness for both companies and the region. The Cluster is co-financed by the European Regional Development Fund (ERDF).

tecnet equity GmbH Booth 46 NiederĂśsterreichring 2, Haus B A-3100 St. PĂślten T. +43 (0)2742 9000 19300 F. +43 (0)2742 9000 19319 madl@tecnet.co.at www.tecnet.co.at

Contact person Mag. Lukas Madl, Technology Transfer Manager

tecnet equity is an agency of Lower Austria with the mission to commercialise inventions and new technologies. tecnet is partner of premier universities and research organisations of Austria moving their research results from the lab to the market and by

that transferring inventions into successful innovations. For our industry partners we enable fast and pragmatic collaborations with academic R&D and provide access to the latest technologies and patents. tecnet also manages a venture capital fund for start-ups.

Themis Bioscience GmbH Booth 46 Muthgasse 11 A-1190 Vienna T. +43 (0)1 236 71 51 F. +43 (0)1 236 71 51 73 info@themisbio.com www.themisbio.com

Contact person Dr. Erich Tauber, CEO

Themis Bioscience GmbH develops vaccines against infectious diseases. The company focuses on emerging tropical infectious diseases and develops vaccines from the preclinical to the early clinical phase. Initial vaccine candidates are currently being developed against Dengue and Chikungunya, with vaccines against other di-

seases a future possibility. The companyâ&#x20AC;&#x2122;s own Themaxyn technology platform, which has been licensed by the internationally respected Pasteur Institute in Paris, forms the basis for all vaccine candidates of the Vienna-based company. This platform is highly innovative and fully protected by patents.

Tikopia Consulting Booth 46 Suedtirolergasse 17â&#x20AC;&#x201C;21/5 A-3423 St. Andrae-Woerdern T. +43 (0)660 4955780 office@tikopia-consult.at www.tikopia-consult.at

Contact person Theodor Langer, CEO

Tikopia Consulting is a consulting company specialized in project and quality management for the pharmaceutical, biotechnology, medical device, and related industry. Our services include Developmental Project Setup and Leadership, International Team Building, Business Development, Preclinical

and Toxicological Consultancy, Quality Management Systems and GMP Audits. We foster a result oriented working style, based on our long experience in the pharmaceutical industry. Customized solutions in close collaboration with our clients are the foundation of our success.

Tissue Med Biosciences Booth 46 Magnesitstrasse 1 A-3500 Krems T. +43 (0)2732 87470 310 office@tmbiosciences.com www.tmbiosciences.com

Tissue Med Biosciences is an Austrian biotech company developing novel therapies for chronic diseases. The lead compound (TMBP-3) is a human recombinant protein for diabetic foot ulcer (DFU), a serious consequence of diabetes type 2. Other proteins in development target indications in the field he-

Contact person Dr. Rudolf Berger, CEO and Founder

matology and musculoskeletal diseases. A clinical phase 1 of TMBP-3 will be initiated in late 2013. TMBP-3 acts not only on skin cells but also on endothelial and immune cells. Therefore, the use is not restricted to DFU, but to patients with decubitus or venous ulcers and other severe wounds.

Tube Pharmaceuticals GmbH Booth 46 Leberstr. 20 A-1110 Vienna T. +43 (0) 1 740935 100 F. +43 (0) 1 740935 900 info@tubepharma.at www.tubepharma.at

Contact person Dr. Wolfgang Richter, Managing Director

Tube is focusing on the development of small molecules derived from natural products for targeting approaches by using its proprietary toxin platforms Tubulysins (Cytolysins) and Epothilones as conjugation payloads for safer and more efficacious therapies. Tubeâ&#x20AC;&#x2122;s own development product is a nanopharmaceutical using a potent

tubulysin which shows an excellent efficacy and safety profile in many in-vivo studies. Tube is also involved in the co-development of other conjugation programs using peptides, proteins or antibodies as targeting principle. In addition, Tube offers synthesis services of complex organic molecules.

ugichem GmbH Booth 46

Mitterweg 24 A-6020 Innsbruck T. +43 (0)512 282285 10 F. +43 (0)512 282285 11 holgerbock@ugichem.at www.ugichem.com

Contact person Dr. Holger Bock, CEO

Based on the innovative UgimerÂŽ platform ugichem is developing innovative antisense therapeutics with a unique therapeutic efficacy profile for immune mediated in-

flammatory diseases (IMID) where existing therapies are insufficient or do not work. ugichem initially focuses on rheumatoid arthritis (RA) as lead indication.

University of Technology Vienna Booth 45 Favoritenstrasse 16 A-1040 Vienna T. +43 (0)1 588014 15243 F. +43 (0)1 588014 15980 hildegard.sieberth@tuwien.ac.at www.rt.tuwien.ac.at

Contact person Dr. Hildegard Sieberth, Patentmanager

The Vienna University of Technology (TU Vienna) is among the most successful technical universities in Europe and is Austria‘s largest scientific-technical research and educational institution. Research areas cover all classic engineering disciplines; many of them are highly

relevant for biotech and medtech industries. TU Vienna for example hosts expertise in bioanalytics and sensor development, biomechanics, biomedical engineering, chemical technologies, electrodynamics, material sciences and software development.

University of Veterinary Medicine Vienna Booth 45 Veterinaerplatz 1 A-1210 Vienna T. +43 (0)1 25077 1047 F. +43 (0)1 25077 1090 christine.ruckenbauer@vetmeduni.ac.at www.vetmeduni.ac.at; www.vetwidi.at

The University of Veterinary Medicine Vienna is the only academic, educational and research institution of veterinary medicine in Austria. Its animal hospital welcomes patients 24/7. It is committed to combine basic and applied clinical research of the highest quality, to meet the challenges of animal health and food safety.

Contact person Mag. Christine Ruckenbauer, Head of Technology Transfer

The main areas of research are: • Physiological processes Infection and prevention, with a focus on farm animals; • Animal models and veterinary biotechnology; • Food safety and risk analysis; • Animal behaviour and human-animal interactions.

University of Vienna Booth 45

University of Vienna Research Services Berggasse 7, 2nd floor A-1090 Vienna T. +43 (0)1 4277 18222 ingrid.kelly@univie.ac.at https://forschung.univie.ac.at/en/technology-transfer/

The University of Vienna was established in 1365, and is currently one of the largest Universities in Central Europe. More than 400 academic staff members are actively engaged in cutting-edge research in the biological and pharmaceutical sciences in the Faculties of Life

Contact person Dr. Ingrid Kelly, Technology Transfer Manager

Sciences and Chemistry, and at the Max F. Perutz Laboratories. The University of Vienna prides itself on its role as a leading provider of education and innovation in fundamental and applied biological research in Austria.

Valneva Austria GmbH Booth 46 Contact person Frédéric Legros, Head of Business Development

Valneva is a new European biotech company focusing on antibody discovery and vaccine development and commercialization. It was created in 2013 through the merger between Intercell AG and Vivalis SA. Valneva generates diversified revenue from both its

Campus-Vienna-Biocenter 3 A-1030-Vienna T. +43 (0)1 206201125 F. +43 (0)1 2062081125 bd@valneva.com www.valneva.com

marketed Japanese encephalitis vaccine (IXIARO®), commercial partnerships around a portfolio of product candidates (in-house and partnered) and licensed technologies (EB66 cell-line, VivaScreen antibody discovery, vaccine adjuvant IC31).

Vela Laboratories GmbH Booth 46 Brunner Straße 69/6 A-1230 Vienna T. +43 (0)1 890597911 F. +43 (0)1 890597910 office@vela-labs.at www.vela-labs.at

Contact person Dr. Markus Fido, CEO Dr. Andreas Nechansky, COO

Vela Laboratories is a world-wide acting, GMP-certified contract laboratory which offers in-depth analytical characterization services for proteins and peptides. Vela’s philosophy is to interact individually with each of our clients. Together we are working out the analytical approach dedicated to meet all regulatory requirements

in accordance with the relevant guidelines. A key expertise of Vela is performing the comparability exercise for Biosimilars like growth factors and monoclonal antibodies. Within this portfolio, also cell-culture-based potency assay, e.g. CDC, ADCC and (anti)-proliferation have been established.

Vienna Business Agency Booth 46 Schmerlingplatz 3 A-1010 Vienna T. +43 (0)1 4000 86949 info.is@vba.at www.vba.at

Vienna Business Agency – Your Start in Vienna We are the first point of contact for national and international companies and investors who are looking to establish a branch in Vienna. As Vienna’s official investment promotion agency, we provide

you with comprehensive information about the business location Vienna, including tailor-made support services, funding and real estate – no matter if you are a start-up or a multinational company. All of our services are free of charge. Visit us online: www.vba.at

ViruSure GmbH Booth 46

Donau-City-Strasse 1 A-1220 Vienna T. +49 (0) 174 319 1173 F. +43 (0)1 269912 022 ralf_klein@virusure.com www.virusure.com

Contact person Dr. Ralf Klein, Manager Business Development

ViruSure GmbH is a privately owned GMP/GLP certified biotech company based in Vienna specialising in virus and prion safety testing of biopharmaceutical products. We offer client focused contract testing services with an expertise ensuring to meet authorities requirements worldwi-

de. Both our in vivo and in vitro testing facilities operate under a state of the art risk based quality management system. The services include: Virus- and Prion Removal Studies, Cell Banking, Cell Line Characterization, Potency Testing, Vaccine Testing, Tumorigenicity and Oncogenocity Studies.

VTU Technology GmbH Booth 46 Parkring 18 A-8074 Grambach T. +43 (0)316 4009 4000 F. +43 (0)316 4009 4010 office.technology@vtu.com www.vtu-technology.com

Contact person Dr. Thomas Purkarthofer, Head Business Development

VTU Technology is a leading contract research and development company providing services for the fast track generation of high performance, industrial protein production strains and economically viable protein production processes from lab to pilot scale. Based on its powerful Pichia pastoris expression platform VTU

offers time-saving development of cost-efficient recombinant protein production processes yielding up to 20 g/L of secreted protein for serum proteins, cytokines, Fabs, antibody derived fragments, (HSA&Fc)fusion proteins, scaffolds, vaccines and enzymes.

Willheim Müller Rechtsanwälte Booth 46 Rockhgasse 6 A-1010 Vienna T. +43 (0)1 535 8008 0 F. +43 (0)1 535 8008 50 office@wmlaw.at www.wmlaw.at

Contact person Dr. Stephan Winklbauer, Partner

Willheim Müller Rechtsanwälte is an independent full service business law office located in Vienna, Austria. We work for global corporations as well as small and medium sized companies, trusts, nonprofit organisations, family offices as well as wealthy individuals. Our practice is business and sector oriented and expands across borders.

Major practice areas of WMLaw: • International Arbitration and Business Litigation • Corporate and M&A • Austrian and EU Competition and Antitrust Law • Foundations and Trusts • Infrastructure Projects (PPP-Proj.) • Real Estate • IP and IT- Law

Xiber Science GmbH Booth 46 Josefigasse 24 A-2353 Guntramsdorf T. +43 (0)699 17054086 s.reingruber@xiberscience.com www.xiberscience.com

Xiber develops first-in-class peptide drugs that prevent organ damage. Xiber’s drugs have the potential to improve survival and outcome of critical care and transplant patients, to reduce the duration of stay at the critical care unit and to alleviate life supportive measures. Initially Xiber will concentrate on following niche indications: Acute

Contact person Dr. Sonja Reingruber

Lung Injury & Primary Graft Dysfunction after Lung Transplantation and prevention of Generalized Edema & Organ Failure in Severe Burn Victims. In a midterm perspective Xiber aims to develop a prophylactic treatment to prevent organ failure in critical care and transplant patients.

Zeta Biopharma GmbH Booth 46 Zetaplatz 1 A-8501 Lieboch/Graz T. +43 (3136) 9010 0 F. +43 (3136) 9010 9100 office@zeta.com www.zeta.com

Contact person Dr. Andreas Marchler, Managing Director

Zeta is specialised in designing, engineering, development, manufacture, automation and maintenance of customised process solutions for aseptic applications. As a recognised technology supplier and R&D partner of the biotechnological and pharmaceutical industry, Zeta has comprehensive competence, experience

and references in: • Up- and downstream systems • Preparation and formulation systems • CIP/SIP- and media systems • Sterile plant installation • Magnetic agitators • Freeze & thaw systems • Automation solutions

ZIT – The Technology Agency of the City of Vienna Booth 46 Ebendorferstrasse 4 A-1010 Vienna T. +43 (0)1 4000 86178 halwachs@zit.co.at

Contact person Peter Halwachs, Consultant

ZIT serves as the technology promotion agency of the City of Vienna. The activities of ZIT encompass providing direct financial assistance (i.e. grants) to companies

or making a technology-specific infrastructure available, as well as the implementation of a broad range of accompanying measures in all phases of the innovation process.

PARTNERING FOR INNOVATION

6 th Annual International Medtech Partnering Conference

EUROMEDTECH

™

2014

MAY 7–8, 2014 LINZ, AUSTRIA

Apply to p Deadline resent now ! : March 7, 2014

DESIGN CENTER LINZ

GET YOUR MEDTECH DEALS DONE AT EUROMEDTECH™ 2014! Optimize your time, make your networking more efﬁcient, and connect directly with high level executives at EuroMedtech™ 2014 in Linz, Austria. Make the connections that matter: partnerships with small companies and large corporations Find suppliers or development partners Reach out to investors Connect with distributors, manufacturers and consultants Identify the right collaborators to get your products to market Explore

Featuring: The user-friendly, industry-speciﬁc connection tool, partneringONE®, that takes the guesswork out of event networking Company presentations and exhibits Panels and workshops that explore the practices of successful companies and the hot technologies that will lead dealmaking activity in the future Evening events at unique venues creating additional informal networking opportunities Find out more at www.ebdgroup.com/emt

Producer

Hosts

Austria at BIO-Europe 2013 Schedule

Company Presentations by Topic Topic: Service/CMO

Tuesday, 5.11.

ACIB GmbH - Austrian Centre of Industrial Biotechnology Topic: Vaccines

Schubert 1 09:00

Tuesday, 5.11.

Schubert 4

Valneva Austria GmbH

11:00

AFFiRiS AG

11:30

Topic: Respiratory

Tuesday, 5.11.

Schubert 4

APEPTICO

14:15

S-TARget therapeutics GmbH

15:00

Topic: Cancer

Tuesday, 5.11.

Schubert 2

Apeiron Biologics AG

15:00

Activartis Biotech GmbH

16:15

Topic: Infectious Disease

Wednesday, 6.11.

Schubert 4

Haplogen

09:15

Marinomed Biotechnologie GmbH

09:45

Monday, 4.11. 09:00 – 10:30 Workshop Collaborative approaches to translational research: Bridging the gap from target to lead Room: Schubert 1 09:45 – 10:30 press conference Booth #46

Tuesday, 5.11.

09:50 – 11:40 Academic Innovators™ Showcase Room: Schubert 5

CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences University of Vienna

14:00 – 16:00 Next Generation Company Presentations Room: Schubert 5

16:00 – 17:00 International Seminar Production and Platform Technologies Room: Schubert 4 17:45 – 18:45 Exhibit Hall Reception "Wiener Würstlstand" Booth # 46 19:00 – 22:30 Evening Networking Reception Town Hall

Organisation

Medical University of Vienna

10:45 – 11:15 Welcome and Opening Remarks Room: Strauss 1/2

14:45 – 15:45 Panel Discussion Public funding in drug development: Analyzing the dose-effect relationship Room: Stolz 2

Wednesday, 6.11.

19:00 – 22:30 Evening Networking Reception Metastadt

Time

Company